Streetbeat News

Products Services

MEG

Montrose Environmental Group has acquired Origins Laboratory, LLC, a NELAP-certified environmental testing laboratory. Origins will be integrated into Montrose's Measurement and Analysis Segment, operating under Enthalpy Analytical, LLC.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:41 am

ELAB

Elevai Labs' subsidiary, Elevai Skincare, has revealed promising results for its E-Series Exosome Technology in treating melasma, especially when combined with laser therapy. The case studies show synergistic effects and no recurrence after six months.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:39 am

VRDN

Viridian Therapeutics shares rose following the release of positive topline data from the THRIVE phase 3 clinical trial of VRDN-001, a treatment for active thyroid eye disease.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:37 am

CNTA

Centessa Pharmaceuticals' stock is rising following the release of positive interim data from a Phase 1 trial of ORX750, a treatment for acute sleep deprivation.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:36 am

AZ

NYAX

Nayax Ltd. and A2Z Cust2Mate Solutions Corp. have partnered to launch a smart cart payment system for retail stores. This collaboration integrates Nayax's payment technology with A2Z's smart cart platform, aiming to enhance the shopping experience by allowing customers to complete purchases directly from their carts. The first deployment will occur in France, with plans for global expansion.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:36 am

BRLS

A study by Texas Tech University found that Borealis Foods' Chef Woo high-protein ramen noodles significantly reduce caloric intake at the next meal.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:36 am

JSPR

Jasper Therapeutics has received approval from Health Canada for a Phase 1b/2a clinical trial of briquilimab, targeting asthma. The trial will begin in Q4 2024, with initial data expected in the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:35 am

CARM

MRNA

Carisma Therapeutics has expanded its collaboration with Moderna to include two targets for autoimmune diseases. Carisma retains rights beyond these targets, which are exclusively partnered with Moderna.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:33 am

CRDL

Cardiol Therapeutics has completed its MAvERIC Phase II study on recurrent pericarditis. The findings will be presented at the 2024 American Heart Association Scientific Sessions.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:33 am

ARWR

Arrowhead Pharmaceuticals received Breakthrough Therapy Designation from the FDA for its investigational drug Plozasiran, aimed at reducing triglycerides in adults with Familial Chylomicronemia Syndrome.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:31 am